News

STAIR XII meeting in Washington DC

EVER Pharma participated in the STAIR conference for the first time
read more

Cerebrolysin® reduces hospital stay in TBI patients

Promising data for TBI patients on World Head Injury Awareness Day
read more
1 … 23 24 25 26 27 … 70
26.06.2025

Cerebrolysin® as an Adjunct Therapy to Mechanical Thrombectomy

New Study highlights Cerebrolysin's potential in improving longterm outcome
Read more
06.06.2025

AMN CONGRESS IN BANGKOK, THAILAND

04 – 05 July, 2025, Pullmann Bangkok King Power
Read more
22.04.2025

ESOC 2025 - Visit the EVER Pharma Symposium

Evidence from 3 new studies
Read more
1 … 23 24 25 26 27 … 35
Go to Archive

Congresses

11th European Stroke Organisation Conference

Helsinki, Finland
21 - 23 May 2025
GO TO EVENT

17th World Stroke Congress

Barcelona, Spain
22 - 25 October 2025
GO TO EVENT

Notice to U.S. Visitors

Please be advised that Cerebrolysin is not registered with the U.S. Food and Drug Administration (FDA) and is not approved for sale or distribution in the United States.

Cerebrolysin is a prescription medication for use under the supervision of an authorized health care professional. For any medical inquiries, please consult with a healthcare professional.